HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Anagrelide compared with hydroxyurea in essential thrombocythemia: a meta-analysis.

Abstract
Cytoreductive therapy, with or without low-dose aspirin, is the mainstay of thrombotic risk reduction in patients with essential thrombocythemia (ET), but the optimal choice of agent remains unclear. The aim of this study was to meta-analyze currently available data comparing anagrelide to hydroxyurea for reduction of rates of thrombosis, bleeding and death among patients with ET. A literature search for randomized, controlled trials comparing anagrelide to hydroxyurea among patients with ET revealed two published studies. Statistical analysis was performed using fixed effects meta-analysis. Rates of thrombosis were similar between patients treated with hydroxyurea vs anagrelide (RR 0.86, 95 % CI 0.64-1.16). Rates of major bleeding were lower in patients treated with hydroxyurea (RR 0.37, 95 % CI 0.18-0.75). Rates of progression to acute myeloid leukemia were not statistically different (RR 1.50, 95 % CI 0.43-5.29). The composite of thrombosis, major bleeding and death favored hydroxyurea (RR 0.78, 95 % CI 0.63-0.97). In conclusion, our analysis supports use of hydroxyurea as a first-line cytoreductive agent for patients with ET, based largely on decreased rates of major bleeding. Anagrelide appears to be equally effective for protection against thrombotic events and may be an appropriate alternative for patients who are intolerant of hydroxyurea.
AuthorsBethany Samuelson, Chatree Chai-Adisaksopha, David Garcia
JournalJournal of thrombosis and thrombolysis (J Thromb Thrombolysis) Vol. 40 Issue 4 Pg. 474-9 (Nov 2015) ISSN: 1573-742X [Electronic] Netherlands
PMID25894476 (Publication Type: Comparative Study, Journal Article, Meta-Analysis, Review)
Chemical References
  • Quinazolines
  • anagrelide
  • Hydroxyurea
Topics
  • Hemorrhage (chemically induced, mortality)
  • Humans
  • Hydroxyurea (adverse effects, therapeutic use)
  • Quinazolines (adverse effects, therapeutic use)
  • Thrombocythemia, Essential (drug therapy, mortality)
  • Thrombosis (chemically induced, mortality)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: